Calyxt

Canaccord Genuity Acts as Exclusive Financial Advisor to Calyxt on its All-Stock Merger with Cibus

Canaccord Genuity is pleased to announce that its client, Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, completed its previously announced merger transaction with Cibus, Inc. a leader in precision gene editing in agriculture on May 31, 2023. The combined company brings together the technology platforms and facilities of two pioneering companies to create a leading agricultural technology company for the development of Productivity Traits and Sustainable Ingredients.

The combined company has over 1,000 patents issued or pending covering a broad range of fundamental enabling technology in gene editing in agriculture. In the first half of 2023, Cibus transferred three different traits in two different crops to customers in their elite germplasm and has three other traits in advanced development. The company is finishing construction of the first trait machine facility which is the industry’s first stand-alone semi-automated trait production facility.

The combined company, renamed Cibus, Inc., trades on the Nasdaq Capital Market under the ticker “CBUS”.

Canaccord Genuity, with a team led by Morgan Ley, David Istock, Jaemin Oh and Tyler Kennedy, served as exclusive financial advisor to Calyxt.